Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
Recent Articles By The Author
Celgene's Siren Song
TheStreet Contributor Nate Sadeghi debates whether to buy Celgene ahead of a European decision on expanding use of its multiple myeloma drug Revlimid.
Outlooks for Pfizer, Arena and Onyx Following Busy May
Healthcare investor Nate Sadeghi says Pfizer's arthritis drug and Arena's obesity drug will be approved, while confidence in Onyx's cancer drug has increased.
A Health Care Fortnight for the Record Books
Health care investor Nate Sadeghi says Pfizer is holding back bad news on its Alzheimer's drug, tells Human Genome to sell to Glaxo and likes Vertex and Gilead Sciences.
Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix
A closer look at Bristol-Myers Squibb's hepatitis C drug BMS-094 raises troubling questions.
Grading Hep C Stocks Exiting EASL Confab
Healthcare investor Nathan Sadeghi-Nejad grades the hepatitis C drug stocks following the closely watched EASL conference.
Gilead, Bristol Hep C Drug Data Arrives at EASL
The closely followed EASL meeting has begun with release of key hepatitis C drug data from Gilead and Bristol-Myers Squibb
Calling Shenanigans on Amylin Pharma
Too many question, not enough answers regarding Bristol-Myers Squibb's supposed interest in buying Amylin.
Gilead And The Future of HIV Therapy
Gilead's market dominance in HIV is not in peril but the company faces legitimate questions about its ability to innovate.
Regeneron, Amgen And The 'Hope Creation Cycle"
Cholesterol-lowering PCSK9 Inhibitors are real drugs but won't meet aggressive sales forecasts
On Nowruz, Reviewing Drug Stock Picks
TheStreet's biotech contributor Nathan Sadeghi-Nejad looks back at his hits and misses with Amylin, Elan, Gilead Sciences, Onyx and Verastem.